EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies

Anna Roshani Dashtmian, Fereshteh B Darvishi, William David Arnold iD

Cells · 2024

DOI: 10.3390/cells13110928 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Anna Roshani Dashtmian und 2 weiteren Autor:innen. Beteiligte Einrichtung: NextGen Precision Health, University of Missouri, Columbia, MO 65211, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Aging. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, national institute of health, National Institute on Aging/National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic Lateral Sclerosis (ALS) is a group of sporadic and genetic neurodegenerative disorders that result in losses of upper and lower motor neurons. Treatment of ALS is limited, and survival is 2–5 years after disease onset. While ALS can occur in younger individuals, the risk significantly increases with advancing age. Notably, both sporadic and genetic forms of ALS share pathophysiological features overlapping hallmarks of aging including genome instability/DNA damage, mitochondrial dysfunction, inflammation, proteostasis, and cellular senescence. This review explores chronological and biological aging in the context of ALS onset and progression. Age-related muscle weakness and motor unit loss mirror aspects of ALS pathology and coincide with peak ALS incidence, suggesting a potential link between aging and disease development. Hallmarks of biological aging, including DNA damage, mitochondrial dysfunction, and cellular senescence, are implicated in both aging and ALS, offering insights into shared mechanisms underlying disease pathogenesis. Furthermore, senescence-associated secretory phenotype and senolytic treatments emerge as promising avenues for ALS intervention, with the potential to mitigate neuroinflammation and modify disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisAgingHumansSenotherapeuticsAnimalsCellular SenescenceMitochondriaDNA Damage

Stichwörter der Autor:innen

agingmotor neuronsarcopeniasenescence

Substanzen

Senotherapeutics

Autor:innen und Institutionen

  • NextGen Precision Health, University of Missouri, Columbia, MO 65211, USA.
  • NextGen Precision Health, Department of Physical Medicine and Rehabilitation, University of Missouri, Columbia, MO 65211, USA.

ORCID-Profile: William David Arnold

Förderung

  • NIA NIH HHS
  • national institute of health
  • National Institute on Aging/National Institute of Health

Zitieren

APA

Dashtmian, A. R., Darvishi, F. B., & Arnold, W. D. (2024). Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies. Cells. https://doi.org/10.3390/cells13110928

Vancouver

Dashtmian AR, Darvishi FB, Arnold WD. Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies. Cells. 2024. doi:10.3390/cells13110928

BibTeX
@article{Dashtmian2024,
  author = {Dashtmian, Anna Roshani and Darvishi, Fereshteh B and Arnold, William David},
  title = {Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13110928}
}
Kostenlos starten →